The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.
Open accessAbstract
The in vivo appearance of soluble interleukin (IL)-6 receptor (sIL-6R) in serum from patients with inflammatory bowel disease was examined using an enzyme linked immunosorbent assay (ELISA). The serum sIL-6R concentrations in patients with active disease (ulcerative colitis, 148.4 (5.1); Crohn's disease, 142.3 (9.3) ng/ml; mean (SEM)) were significantly raised compared with those in patients with inactive disease (ulcerative colitis, 116.2 (7.2); Crohn's disease, 114.3 (7.1) ng/ml), some other type of colitis (104.8 (11.6) ng/ml), or in normal subjects (107.3 (2.4) ng/ml). These differences were also seen in paired samples examined during both active and inactive phases. Additionally, serum sIL-6R and IL-6 concentrations correlated significantly with C-reactive protein levels in both ulcerative colitis and Crohn's disease patients (r = 0.23 and 0.56, respectively; p < 0.05 for both). Furthermore, gel filtration analysis of serum from these patients showed two major peaks of immunoreactive IL-6-one peak corresponding to free IL-6 and another peak to sIL-6R-bound IL-6-this was further confirmed by a luminescence sandwich ELISA. These results, together with its in vitro effects, indicate that natural sIL-6R may function as a powerful enhancer of the IL-6-dependent immune processes observed in inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease
Guan, Q. (2019) · Journal of Immunology Research · doi:10.1155/2019/7247238 · Cited by 1,065
Is obesity an inflammatory condition?
Das, U. N. (2001) · Nutrition · doi:10.1016/s0899-9007(01)00672-4 · Cited by 799
Role of cytokines in inflammatory bowel disease
Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4280 · Cited by 699
Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway
Maggio, M., Guralnik, J. M., Longo, D. L., & Ferrucci, L. (2006) · The Journals of Gerontology: Series A · doi:10.1093/gerona/61.6.575 · Cited by 692
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
Neurath, M. F., & Finotto, S. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.003 · Cited by 576
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance
Mudter, J., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20148 · Cited by 436
IL-6 is required for the development of Th1 cell-mediated murine colitis
Yamamoto, M., Yoshizaki, K., Kishimoto, T., & Ito, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4878 · Cited by 411
“The soluble form of IL-6R (sIL-6R) is also elevated (6), and this is known to potentiate IL-6 activity by forming IL-6-sIL-6R complexes that bind the signaling-competent transmembrane receptor gp130 (7).”
BackgroundEastaff-Leung, N., Mabarrack, N., Barbour, A., Cummins, A., & Barry, S. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9345-1 · Cited by 392
Immune response and inflammatory pathway of ulcerative colitis
Tatiya-aphiradee, N., Chatuphonprasert, W., & Jarukamjorn, K. (2018) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2018-0036 · Cited by 368
The IL-6/sIL-6R complex as a novel target for therapeutic approaches
Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., & Seegert, D. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.613 · Cited by 360
Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Atreya, R., & Neurath, M. F. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:187 · Cited by 324
Therapeutic Targeting of the Interleukin-6 Receptor
Tanaka, T., Narazaki, M., & Kishimoto, T. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134715 · Cited by 262
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Immune dysfunction in inflammatory bowel disease
Neuman, M. G. (2007) · Translational Research · doi:10.1016/j.trsl.2006.11.009 · Cited by 255
Baran, P., Hansen, S., Waetzig, G. H., Akbarzadeh, M., Lamertz, L., Huber, H. J., Ahmadian, M. R., Moll, J. M., & Scheller, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001163 · Cited by 235
Positioning and usefulness of biomarkers in inflammatory bowel disease
Sakurai, T., & Saruta, M. (2023) · Digestion · doi:10.1159/000527846 · Cited by 156
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology
Giraldez, M. D., Carneros, D., Garbers, C., Rose-John, S., & Bustos, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00473-x · Cited by 156
Reinisch, W., Gasché, C., Tillinger, W., Wyatt, J., Lichtenberger, C., Willheim, M., Dejaco, C., Waldhör, T., Bakos, S., Vogelsang, H., et al. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01288.x · Cited by 150
Biologic Control of Injury and Inflammation: Much More than Too Little or Too Late
Guirao, X., & Lowry, S. F. (1996) · World Journal of Surgery · doi:10.1007/s002689900069 · Cited by 102
Kovacs, E. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00079-8 · Cited by 33
Li, Y., Lu, L., & Androulakis, I. P. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.005 · Cited by 17
Metadata
- Authors
- Mitsuyama, K., Toyonaga, A., Sasaki, E., Ishida, O., Ikeda, H., Tsuruta, O., Harada, K., Tateishi, H., Nishiyama, T., & Tanikawa, K.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1995-01
- Volume
- 36
- Issue
- 1
- Pages
- 45-49
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2135575955
- Cited by
- 186
- References
- 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.